R 1511
Alternative Names: GK 3; Glucokinase activator (3); R1511Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Roche
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 16 Apr 2009 Discontinued - Phase-I for Type-2 diabetes mellitus in Europe (PO)
- 20 Oct 2008 Roche completes a phase I trial in Type-2 diabetes mellitus in Europe
- 19 Mar 2007 Phase-I clinical trials in Type-2 diabetes mellitus in Europe (PO)